STATISTICAL ASSESSMENT OF MEAN DIFFERENCES BETWEEN TWO DISSOLUTION DATA SETS*
|
|
- Bartholomew Malone
- 5 years ago
- Views:
Transcription
1 Drug Information Journal, Vol. 30, pp , /96 Printed in the USA. All rights reserved. Copyright 1996 Drug Information Association Inc. STATISTICAL ASSESSMENT OF MEAN DIFFERENCES BETWEEN TWO DISSOLUTION DATA SETS* YI TSONG, PHD, AND THOMAS HAMMERSTROM, PHD Office of Epidemiology and Biometrics PRADEEP SATHE, PHD, AND VINOD P. SHAH, PHD Office of Pharmaceutical Sciences Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland When comparing the dissolution data of a postapproval change product and a reference approval product, the goal is to assess the similarity between the mean dissolution values at the observed sample time points. The decision on accepting or rejecting the hypothesis that the two batches have similar dissolution is based on the evidence regarding whether the difference in mean dissolution values between the test and reference products is no larger than the maximum expected difference between any two batches of the approval product. When dissolution value is measured at a single time point, the confidence interval of the true difference between the two batches is compared with the prespecified similarity limits. When dissolution values are measured at multiple time points, a multivariate statistical procedure for difference assessment can be a generalized form of the t-statistic procedure. The proposed procedure is a modification and generalization of the regular bioequivalence test concept. The application of the proposed multivariate analysis procedure is illustrated using an example. Key Words: Dissolution test; Multivariate analysis of variance; Confidence region; Similarity test INTRODUCTION based on dissolution testing data are often accepted as adequate to assure dosage form DISSOLUTION DATA OF the drug product similarity and hence in vivo performance. are often used to assess the dosage form simi- The similarity of the product with respect to larity when the drug manufacturer is making dissolution means that the test (postapproval scale-up and postapproval changes, namely change) product has a dissolution performanufacturing site change, component and mance no different than that expected from compositional changes, and equipment and the reference (prechange) product except for process changes (1). Changes approved the potential batch-to-batch or lot-to-lot variation. Hence, in developing a statistical assess- *The views expressed in this paper are professional opinions of the authors and may not necessarily repredissolution data sets, the following need to ment of the difference between means of two sent the position of the U.S. Food and Drug Administration. be considered: Reprint address: Yi Tsong, Division of Biometrics III, HFD-720, Office of Epidemiology and Biostatistics, Center for Drug Evaluation and Research, FDA, A well-defined similarity limit of the pre- Fishers Lane, Rockville, MD change product is established before com- 1105
2 1106 Yi Tsong, Thomas Hammerstrom, Pradeep Sathe, and Vinod P. Shah paring the dissolution data of the test and proposes a statistical test for the hypothesis reference batches. The similarity limit is that the two batches are globally similar. set either by the knowledge of the characteristics of the product or by the empirical SINGLE TIME POINT experience on the batch-to-batch and the DISSOLUTION VALUE within-batch difference of the existing reference product. Similarity limits can be For most immediate release drug products, defined as global similarity or uniformly the dissolution is rapid and the quality control local similarity. Typically, a global similar- dissolution requirement is only a single time ity limit D g is defined as a tolerable differ- point measurement. By considering the disence between the test batch and the refer- solution measurement as a variable, the difence batch over all time points. The limit ference between the mean dissolution values D g is often defined as a given percentage of the test and reference product can be easily of dissolution, say, 10%. But with any measured and standardized with the regular measurement of difference, the similarity t-statistic. There is an expected difference limit is defined by the measurement corre- based on the empirical experience of the sponding to D g instead of D g itself. On batch-to-batch variation of mean dissolution the other hand, uniform local similarity is values of the reference product. Since the defined as maximum tolerable difference difference between mean dissolution values D t, at each sample time point. It is often of the test and reference batches is an estidefined as a given percentage of dissolu- mate based on the sampled tablets, a confition at time t, say, 12%. The similarity dence interval of the true difference can be limit is then defined by the difference mea- estimated and used when comparing with the surement at each time point and should expected difference. ref lect the similarity of the estimated batch For example, assume that the reference dissolution profiles, product dissolves rapidly and had one mea- 2. When the dissolution data of the reference surable dissolution value that is less than product vary significantly from batch to 100%. The average dissolution value based batch, similarity limits become large and on 12 tablets of a standard batch is 78.5% meaningless. In this case, dissolution data and maximum batch-to-batch difference of of test and reference batches may not be the standard batches is no more than 7.5%. comparable for similarity, With the manufacturing site change, the man- 3. The dissolution measurements of the test ufacturer did dissolution testing of 12 tablets and the reference batches are made under of the new batch after the site change (test identical conditions with an identical num- batch) and 12 tablets of a reference batch ber of units. The reference batch used manufactured recently at the old site. The should be the most recently manufactured dissolution values are given in the following prechange product, example. 4. The conclusion of similarity is made with the consideration of the adequacy of the Example 1 representativeness of the dissolution profiles (calculated with the sample tablets) Test batch Reference batch of the test and reference batches, and Dissolution values are sampled at the time points that properly and adequately repre sent the dissolution profile of the product Mean This paper proposes a statistical assessment of the difference between the mean dissolutions Std of the test and reference products and The difference, D, between test and reference
3 Assessing Differences Between Two Dissolution Data Sets 1107 batch is 2.32%. The standard error of difference, stderr(d), is: ( )/11 = Then the 90% confidence interval of D would be the interval that contains all the differences µ 2 µ 1 such that: [(µ 2 µ 1 ) D]/stderr(D) t 22,.95.(1) where S pooled = (S 1 + S 2 )/2 is the sample vari- ance-covariance matrix pooled across both batches, x 1 = (x 11,x 12,...,x 1p ) is the sample mean dissolution of the reference batch, and x 2. is the sample mean dissolution of the test batch. For the mean difference of two batches in dissolution measurements at multiple time points, the confidence region (CR), is defined as: Where t 22,.95 is the 95th percentile of t distribution with degrees of freedom = 22, that is, 2n 2. The lower and upper limits of the interval L90 and U90 can be calculated by (2): L90 = 2.32 t 22,.95 stderr(d) = U90 = t 22,.95 stderr(d) = Since both the lower and upper 90% confidence limits are within the inter-batch variation, ±7.5% ( 7.5% 0.639% and 4.001% 7.5%), the product after change is accepted as a product with a dissolution value similar to that of the prechange product batch. MULTIPLE TIME POINT DISSOLUTION ment at each time point may be considered a variable. Variation in dissolution changes with time. These variables represent dissolution of one tablet at different time points, which are correlated. The use of the single time point approach then becomes erroneous, necessitating a new difference measurement. A statistical distance often used to mea- sure the difference between two multivariate means is the Mahalanobis distance (M-distance) (3): D M = [(x 2 x 1 ) S 1 pooled(x 2 x 1 )], (2) CR = K[(y (x 2 x 1 )) S 1 pooled(y (x 2 x 1 )] F P, 2n P 1,.90, (3) When the dissolution values are measured at where y = (µ 21 µ 11, µ 22 µ 12,...,µ 2P µ 1P ) multiple time points, dissolution measure- is the difference within CR, K = [(n 2 )/(2n)] TABLE 1 Dissolution Data of a Reference Batch and a Test Batch % Dissolution Batch Tablet 5-min 10-min 15-min 20-min 30-min 60-min 90-min 120-min REF REF REF REF REF REF MEAN TEST TEST TEST TEST TEST TEST MEAN
4 1108 Yi Tsong, Thomas Hammerstrom, Pradeep Sathe, and Vinod P. Shah FIGURE 1. Mean dissolution of the test and reference batches. (2n P 1)/[(2n 2)P], and F P, 2n P 1,.90 is the respectively, the two M-distances of the two 90th percentile of F-distribution with degrees values in CR that give the minimum and of freedoms P and 2n P 1. The multivari- maximum M-distance to the original (the ate confidence region is compared with the l point of no dissolution difference). D M = 0if overall similarity limits for overall similarity. l CR contains the origin. Otherwise, D M and It is to be noted that formula (1) is a special D u M can be calculated using Lagrange Multicase of formula (3) when P = 1. plier method (4). The global similarity can Formula (3) gives a p-variate 90% confidence be verified if the 90% confidence interval: region for the possible true differences. l Let D M be the lower 90% limit, and D u M be the (D l M,D u M ) upper 90% limit of the confidence interval of l true M-distance D M..D M and D u M represent, is imbedded in:
5 Assessing Differences Between Two Dissolution Data Sets 1109 TABLE 2 Variance-Covariance Matrices of the Reference and Test Batches Time Point 5-min 10-min 15-min 20-min 30-min 60-min 90-min 120-min REF 5-min S1 10-min min min min min min min TEST 5-min S2 10-min min min min min min min ( {[D g ] S 1 pooled[d g ]], {[D g ] S 1 pooled[d g ]}), where [D g ] is the 1 P vector with all entries (x 2 x 1 ) =( 17.54, 3.39) K = [6 6/(6 + 6)][( )/ [( )2] = 1.35 equals to D g, the difference specified as the global similar limit. The application of the n 1 + n 2 p 1 = 9, F 2,9,.90 = 3.01 procedure is illustrated in the following two examples (Table 1). CR = {1.35 (µ 21 µ 11 ) (µ 22 µ 12 ) 3.39 Data The dissolution data and the corresponding mean dissolution of the test batch and the reference batch are given in Table 2 and Fig- ((µ 21 µ 11 ) , ure 1. Let S 1 and S 2 denote the sample covari- (µ 22 µ 12 ) 3.39) 3.01} ance matrices of dissolutions at the eight time points for the test and reference batches, rewhere (µ 21 µ 11 ) and (µ 22 µ 12 ) are the possispectively, as shown in Table 3. The mean profiles of test and reference batches will ble value of difference at 15- and 90-minutes be compared for similarity. Let D g be the respectively. The confidence region is shown empirically defined limit, which is obtained in Figure 2. from the standard batches of the reference product. D M = DATA1 data (comparing the 15- and 90-minute sample time points only): For comparing test and reference batches P = 2, n = 6, S pooled = (S 1 + S 2 )/2, The points ((µ 21 µ 11 ), (µ 22 µ 12 )) on the boundary of CR with the minimum and the maximum M-distance from (0, 0), the origin, are ( 15.03, 2.90) and ( 20.05, 3.87), respectively. The 90% confidence interval of D (D l M,
6 1110 Yi Tsong, Thomas Hammerstrom, Pradeep Sathe, and Vinod P. Shah FIGURE 2. The 90% confidence region of difference in percentage dissolved between batches at 15- and 90-minutes. D u M ), is (8.95, 11.93). This is to be compared P = 8, n = 6, S pooled = (S 1 + S 2 )/2, with: (x 2 x 1 ) =( 23.69, 20.52, 17.54, 14.80, RD = {[15] S 1 pooled[15]} = , 3.39, 5.00) T 2 = Since is larger than 9.63, it is concluded that the two batches are not globally K = [6 6/(6 + 6)[( )/ similar. [( )8] =.1125 DATA2 data (Comparing all eight time D M = points): (D l M,D u M )=(19.65, 33.32)
7 Assessing Differences Between Two Dissolution Data Sets 1111 TABLE 3 Dissolution Data of Two Approved Standard Batches % Dissolution Batch Tablet 5-min 10-min 15-min 20-min 30-min 60-min 90-min 120-min STD STD STD STD STD STD MEAN STD STD STD STD STD STD MEAN Since D u M is greater than RD, it is concluded percentile value. With a fixed number of tablets, that the two batches are not globally similar. more measurements (time points) may lead to a better representation of dissolution DISCUSSION information. Since the second degrees of freedom of F is 2n P 1, however, the When dissolution is measured at multiple maximum number of time points that can be time points, the statistic of Mahalanobis disdramatically used is 2n 2. The F percentile increases tance is used to assess the difference between with the decrease of the second the means of two sets of data with adjustment degrees of freedom. It leads to a large confi- for difference in measurement variation at dence region and a large confidence interval different time points and for the correlation of M-distance. A model-dependent proce- among the measurements at multiple time dure may also be used in such cases. points. Under the assumption that the dissotributed When the data are neither normally dis- lution measurement is multivariate normally or lognormally distributed, one distributed and that the two batches have the needs to consider the nonparametric or bootidentical variance-covariance structure, the strapping procedures. With within-batch dis- 90% confidence interval of the M-distance solution variation being small, decisions can be estimated. When the 90% confidence made with point estimation are sometimes interval is imbedded within the similarity used. They should, however, be used cau- limits, the true difference between the test tiously and conservatively. For example, for and reference batches is no more than the 12 tablets in each batch and with a coefficient expected true difference between two batches of variation of less than 0.10, instead of using of the same product as the reference batch. 15% difference as similarity limit, one may When the data are not normally distributed use 10% instead. one may consider using a lognormal distribution assumption; similarity interpretation is Acknowledgment The authors thank Drs. Roger Wilon the means of the log transformed distribuliams, Lawrence Lesko, and William Fairweather for tion values. their support and encouragement, and CDER s Immedi- As shown in the formula, the confidence ate Release Dissolution Working Group for their suggestions region is the ellipsoid restricted by the F and discussions.
8 1112 Yi Tsong, Thomas Hammerstrom, Pradeep Sathe, and Vinod P. Shah REFERENCES 2. Snedecor GW, Cochran WG. Statistical Methods. Seventh Edition. Ames, IO: The Iowa State University 1. Guidance for Industry, Immediate Release Solid Oral Press; Dosage Forms Scale-Up and Post-Approval changes, 3. Johnson RA, Wichern DW. Applied Multivariate Chemistry, Manufacturing and Controls. In Vitro Dissolution Analysis. Englewood Cliffs, NJ: Prentice-Hall, Inc.; Testing, and In Vivo Bioequivalence Docu mentation. Rockville, MD; Center for Drug Evaluation 4. Freund JE. Mathematical Statistics. Englewood and Research, FDA; November Cliffs, NJ: Prentice-Hall, Inc., 1962.
Application of Statistical Methods to Analyze Groundwater Quality
Journal of Earth Sciences and Geotechnical Engineering, vol. 1, no.1, 2011, 1-7 ISSN: 1792-9040(print), 1792-9660 (online) International Scientific Press, 2011 Application of Statistical Methods to Analyze
More informationDecision Tree for Dissolution Profile Comparison in Product Quality Assessment of Similarity
Decision Tree for Dissolution Profile Comparison in Product Quality Assessment of Similarity September 13, 2018 Yanbing Zheng, Jian-Hwa Han, James Reynolds, Mark Johnson, Karin Rosenblatt, Tzuchi R Ju,
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationStatistical Evaluation Of Stability Data
Reprinted from FDA s website by #219 GUIDANCE FOR INDUSTRY Statistical Evaluation Of Stability Data VICH GL51 DRAFT GUIDANCE This guidance document is being distributed for comment purposes only Submit
More informationSTATISTICAL TOOLS FOR ASSIGNING POTENCY TO REFERENCE STANDARDS
STATISTICAL TOOLS FOR ASSIGNING POTENCY TO REFERENCE STANDARDS Yi Tsong, Xiaoyu Dong & Meiyu Shen yi.tsong@fda.hhs.gov Division of Biometrics VI, Office of Biostatistics, CDER, FDA *This presentation represents
More informationGuidance for Industry
Guidance for Industry ANDAs: Blend Uniformity Analysis DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationSample Size and Power Calculation for High Order Crossover Designs
Sample Size and Power Calculation for High Order Crossover Designs Roger P. Qu, Ph.D Department of Biostatistics Forest Research Institute, New York, NY, USA 1. Introduction Sample size and power calculation
More informationCONFIDENCE INTERVALS FOR THE COEFFICIENT OF VARIATION
Libraries Annual Conference on Applied Statistics in Agriculture 1996-8th Annual Conference Proceedings CONFIDENCE INTERVALS FOR THE COEFFICIENT OF VARIATION Mark E. Payton Follow this and additional works
More informationGuidance for Industry
Guidance for Industry Handling and Retention of BA and BE Testing Samples U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 2004
More informationA Hypothesis Test Perspective on Content Uniformity Test. Lanju Zhang Data and Statistical Sciences AbbVie Inc
A Hypothesis Test Perspective on Content Uniformity Test Lanju Zhang Data and Statistical Sciences AbbVie Inc Disclosure Lanju Zhang is an employee of Abbvie Inc. The presentation was sponsored by AbbVie.
More informationReview of the EMEA Guidelines In-Vitro Equivalence Criteria for Cascade Impaction Data. Dennis Sandell. S5 Consulting
Review of the EMEA Guidelines In-Vitro Equivalence Criteria for Cascade Impaction Data Dennis Sandell S5 Consulting 2010-Sep-09 / dennis@s5consulting.com Outline Background EU Guidance CMPM/EWP/4151/00
More informationA Parametric Tolerance Interval Test for Improved Control of Delivered Dose Uniformity of Orally Inhaled and Nasal Drug Products
International Pharmaceutical Aerosol Consortium on Regulation and Science 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 2 21 22 23 24 25 26 27 28 29 3 31 32 33 34 35 36 37 38 39 4 41 A Parametric Tolerance
More informationEVALUATION FOR STABILITY DATA
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION FOR STABILITY DATA Q1E Recommended for
More informationRegulatory Requirements of Dissolution for Generic Drug Products
Regulatory Requirements of Dissolution for Generic Drug Products Om Anand, Ph.D. Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality - CDER, US-FDA International
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationA Science Based Approach for Topical Drug Classification System
A Science Based Approach for Topical Drug Classification System Vinod P. Shah, Ph.D., FAAPS, FFIP. Pharmaceutical Consultant, (Formerly with US FDA) North Potomac, MD., USA Disso Europe 2016 Romania Advances
More informationUS FDAs Perspective on Product Quality and Bioequivalence
US FDAs Perspective on Product Quality and Bioequivalence Vinod P. Shah, Ph. D. Pharmaceutical Consultant (Formerly with US FDA) Scientific Principles in Dissolution Methodology and Drug Testing Society
More informationScientific and Regulatory Standards for Assessing Product Performance Using the Similarity Factor, f2
The AAPS Journal, Vol. 17, No. 2, March 2015 ( # 2015) DOI: 10.1208/s12248-015-9723-y Commentary Theme: Pharmacokinetics, Biopharmaceutics and Bioequivalence: History and Perspectives Guest Editors: Marilyn
More informationGuidance for Industry
Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationThe Science of Topical Drug Classification System
The Science of Topical Drug Classification System Vinod P. Shah, Ph.D., FAAPS, FFIP. Pharmaceutical Consultant, PQRI, Board Member North Potomac, MD., USA 3 rd FDA / PQRI Conference on Advancing Product
More informationOvercome the Top Challenges of Handling OOS Results by Knowing FDA Observations
Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations Jerry Lanese Ph.D. The Lanese Group, Inc. 2015 The Lanese Group, Inc. 1 Who decided you should come to this conference? On
More informationBCS, Biowaivers and Dissolution Test Methodologies
BCS, Biowaivers and Dissolution Test Methodologies Vinod P. Shah, Ph.D., FAAPS, FFIP Pharmaceutical Consultant, (Formerly with US FDA) North Potomac, MD., USA Disso Europe 2016 Romania Advances and Applications
More informationDissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry U.S. Department of Health and Human
More informationVICH GL51: Quality: statistical evaluation of stability data
1 2 3 12 December 2011 EMA/CVMP/VICH/858875/2011 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 VICH GL51: Quality: statistical evaluation of stability data Draft Draft agreed by VICH Steering
More informationGeneric Basis Values and Acceptance Criteria for Composite Materials
Journal of Materials Science Research; Vol. 4, No. 2; 2015 ISSN 1927-0585 E-ISSN 1927-0593 Published by Canadian Center of Science and Education Generic Basis Values and Acceptance Criteria for Composite
More informationMethods for Identifying Out-of-Trend Data in Analysis of Stability Measurements Part II: By-Time-Point and Multivariate Control Chart
Peer-Reviewed Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements Part II: By-Time-Point and Multivariate Control Chart Máté Mihalovits and Sándor Kemény T his article is a
More informationGuidance for Industry
Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes
More informationINTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!
INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean
More informationEssentials in Stability Analysis and Expiry Determination
Published in BioPharma International. Essentials in Stability Analysis and Expiry Determination Thomas A. Little Ph.D. 6/12/2013 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland,
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Lloyd Inc. of Iowa
More informationGuidance for Industry
Guidance for Industry Powder Blends and Finished Dosage Units Stratified In-Process Dosage Unit Sampling and Assessment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationExpiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance for Industry
Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationBiowaivers: BCS and IVIVC
Workshop in Celebration of 25 th Anniversary of the School of Pharmacy School of Pharmacy Faculty of Medicine The Chinese University of Hong Kong Biopharmaceutics of Modified Release Products and Challenging
More informationPredictability & Performance Through the Product Lifecycle Thought Provoking Perspectives
Quality by Design & Clinical Relevance: Moving Forward Predictability & Performance Through the Product Lifecycle Thought Provoking Perspectives Roger Nosal 1 & Ravi Shanker 2 1 Vice President & Head Global
More informationIntroduction and Background
Quality by Design for Everyone Presented by Brooks Henderson, CQE (Email: Brooks@statease.com) February 26, 2013 Brooklyn Center, MN 8.00 7.00 6.00 5.00 4.00 3.00 200 2.00 Quality Sweet Spot 3.00 4.00
More informationClinically Relevant Specifications (CRS): A Regulatory Perspective
Clinically Relevant Specifications (CRS): A Regulatory Perspective Richard (Rik) Lostritto, Ph.D. Acting Deputy Director for Science & Policy and Acting Biopharmaceutics Lead, Office of New Drug Quality
More informationThe effect of elements of service marketing mix on brand equity, from the customers point of view (Case study: branches of Melli Bank in Hamadan)
The effect of elements of service marketing mix on brand equity, from the customers point of view (Case study: branches of Melli Bank in Hamadan) Shiva Fathian Department of Management and Accounting,College
More informationGuidance for Industry
Guidance for Industry Bioanalytical Methods Validation for Human Studies DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationStatistics and Pharmaceutical Quality
Statistics and Pharmaceutical Quality Karthik Iyer (CQE, CSSBB) Senior Policy Advisor CDER/OC/OMPQ January 24 th, 2014 IFPAC * This presentation reflects the views of the author and should not be construed
More informationEFFICACY OF ROBUST REGRESSION APPLIED TO FRACTIONAL FACTORIAL TREATMENT STRUCTURES MICHAEL MCCANTS
EFFICACY OF ROBUST REGRESSION APPLIED TO FRACTIONAL FACTORIAL TREATMENT STRUCTURES by MICHAEL MCCANTS B.A., WINONA STATE UNIVERSITY, 2007 B.S., WINONA STATE UNIVERSITY, 2008 A THESIS submitted in partial
More informationApplied Multivariate Statistical Modeling Prof. J. Maiti Department of Industrial Engineering and Management Indian Institute of Technology, Kharagpur
Applied Multivariate Statistical Modeling Prof. J. Maiti Department of Industrial Engineering and Management Indian Institute of Technology, Kharagpur Lecture - 20 MANOVA Case Study (Refer Slide Time:
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationAppendix B: Assessing the Statistical Significance of Shifts in Cell EC 50 Data with Varying Coefficients of Variation
120 Appendix B: Assessing the Statistical Significance of Shifts in Cell EC 50 Data with Varying Coefficients of Variation B.1 Introduction Because of the high levels of variability in cell EC 50 (cec
More informationGuidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation
Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center
More informationUnderstanding and accounting for product
Understanding and Modeling Product and Process Variation Variation understanding and modeling is a core component of modern drug development. Understanding and accounting for product and process variation
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationContinuous Manufacturing PMDA s Perspective
Continuous Manufacturing PMDA s Perspective Yoshihiro Matsuda, Ph.D. Senior Scientist (for Quality) Pharmaceuticals and Medical Devices Agency (PMDA) Sep 27, 2016 ISCMP 1 A Background ICH(1) One of the
More informationIn silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation
In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation Uthpali Mannapperuma Mahidol University Department of Pharmacy, Faculty of Pharmacy,
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationBIOEQUIVALENCE TRIAL INFORMATION
PRESENTATION OF BIOEQUIVALENCE TRIAL INFORMATION BIOEQUIVALENCE TRIAL INFORMATION GENERAL INSTRUCTIONS: Please review all the instructions thoroughly and carefully prior to completing the Bioequivalence
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationHarmonizing Standards and Specifications
WASHINGTON REPORT Harmonizing Standards and Specifications Jill Wechsler Manufacturers seek more FDA guidance about establishing product specifications during drug development as part of the agency s efforts
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationRole of PBPK based virtual trials modeling in generic product development and regulation
Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL DISSOLUTION This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of medicines. It represents the Medicines Control
More informationTHE ROLE OF NESTED DATA ON GDP FORECASTING ACCURACY USING FACTOR MODELS *
Andrejs Bessonovs University of Latvia, Latvia THE ROLE OF NESTED DATA ON GDP FORECASTING ACCURACY USING FACTOR MODELS * Abstract The paper studies an impact of nested macroeconomic data on Latvian GDP
More informationwith an Example of for an HPLC Procedure
Peer Reviewed: Analytical Procedure Journal of Validation Technology The Use of the Analytical Target Profile in the Lifecycle of an Analytical Procedure with an Example of for an HPLC Procedure Jane Weitzel,
More informationBiowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA
Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA PQRI BTC Webinar December 06, 2018 DISCLAIMER The presentation
More informationEquivalency Testing: The roles of assay precision, truth, bias, tolerance, risk and control strategy in setting equivalence margins
Equivalency Testing: The roles of assay precision, truth, bias, tolerance, risk and control strategy in setting equivalence margins Kim E. Zerba, Sutan Wu 1 and Gary McGeorge Bristol-Myers Squibb, New
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationConfidence Critical to Batch Release
Confidence Critical to Batch Release Application of ASTM E2709 Standard Practice for Demonstrating Capability to Comply with a Lot Acceptance Procedure and Its Relationship to USP Standards 1 Product Research
More information(MPY-201 DRA) - ADVANCE DRA I
(MPY-201 DRA) - ADVANCE DRA I (Indian Legislation) The Drugs and Cosmetics act, 1940 and Rules with emphasis on Good laboratory practices and requirements of premises and equipments (Schedule L-I), Good
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 6 Inspections, Compliance, Enforcement, and Criminal Investigations Sitek Research Laboratories 5/21/09 Department of Health and Human Services Public Health Service Food and Drug Administration
More informationUSP s Perspective on Drug Product Performance Test
USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development
More informationGENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES
July 2013 RESTRICTED 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES REVISED
More informationMultilevel Modeling Tenko Raykov, Ph.D. Upcoming Seminar: April 7-8, 2017, Philadelphia, Pennsylvania
Multilevel Modeling Tenko Raykov, Ph.D. Upcoming Seminar: April 7-8, 2017, Philadelphia, Pennsylvania Multilevel Modeling Part 1 Introduction, Basic and Intermediate Modeling Issues Tenko Raykov Michigan
More informationComplexity of Retention Samples Selection in non-traditional Bioequivalence studies
Complexity of Retention Samples Selection in non-traditional Bioequivalence studies Nageshwar R Thudi Ph.D. Director-Clinical R&D Teva Pharmaceuticals Disclaimer The views expressed herein are the views
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationHow Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products
How Research Can Help Us Rethink Lifecycle Management and Post- Approval Changes: Oral Products James E. Polli jpolli@rx.umaryland.edu September 17, 2014 Perspective The societal promotion of generic products
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationRe: Docket No. FDA-2017-D-5525: Statistical Approaches to Evaluate Analytical Similarity
November 21 st, 2017 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-D-5525: Statistical Approaches to Evaluate
More informationDetermining the microbiological criteria for lot rejection from the performance objective or food safety objective
International Journal of Food Microbiology 110 (2006) 263 267 www.elsevier.com/locate/ijfoodmicro Determining the microbiological criteria for lot rejection from the performance objective or food safety
More informationSECTION 11 ACUTE TOXICITY DATA ANALYSIS
SECTION 11 ACUTE TOXICITY DATA ANALYSIS 11.1 INTRODUCTION 11.1.1 The objective of acute toxicity tests with effluents and receiving waters is to identify discharges of toxic effluents in acutely toxic
More informationPROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.1 April 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
More informationConfidence Interval Estimation
Confidence Interval Estimation Prof. dr. Siswanto Agus Wilopo, M.Sc., Sc.D. Department of Biostatistics, Epidemiology and Population Health Faculty of Medicine Universitas Gadjah Mada Biostatistics I:
More informationDiscriminant Analysis Applications and Software Support
Mirko Savić Dejan Brcanov Stojanka Dakić Discriminant Analysis Applications and Stware Support Article Info:, Vol. 3 (2008), No. 1, pp. 029-033 Received 12 Januar 2008 Accepted 24 April 2008 UDC 311.42:004
More informationSample Sizes in Uniformity Measurements The Role of USP
Sample Sizes in Uniformity Measurements The Role of USP Anthony J. DeStefano, Ph.D. Walter W. Hauck, Ph.D. Vice President, General Chapters Sr. Scientific Fellow US Pharmacopeia US Pharmacopeia Part I
More informationProcess Characterization Essentials Part I: Process
Process Characterization Essentials Part I: Process Understanding and Health Authorities Guidance Thomas A. Little Ph.D. 2/16/2017 President, Thomas A. Little Consulting, Bioassay Sciences 12401 N Wildflower
More informationDEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION
DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION Guideline Title Development Pharmaceutics and Process Validation Legislative basis Directive 75/318/EEC as amended Date of first adoption April 1988 Date
More informationNonparametric Stepwise Procedure for Identification of Minimum Effective Dose (MED)
International Journal of Statistics and Systems ISSN 097-675 Volume, Number (06), pp. 77-88 Research India Publications http://www.ripublication.com Nonparametric Stepwise Procedure for Identification
More informationTransactions, American Geophysical Union Volume 35, Number 4 August 1954
Transactions, American Geophysical Union Volume 35, Number 4 August 1954 A METHOD FOR DETERMINING THE MINIMUM DURATION OF WATERSHED EXPERIMENTS Jacob L. Kovner and Thomas C. Evans Abstract--A simple graphic
More informationGuidance for Industry
Guidance for Industry Q8, Q9, and Q10 Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationGuidance for Industry
Guidance for Industry Q1F Stability Data Package for Registration Applications in Climatic Zones III and IV U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationA new principal component analysis-based approach for testing similarity of drug dissolution profiles
european journal of pharmaceutical sciences 34 (2008) 66 77 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/ejps A new principal component analysis-based approach for testing
More informationCharacterization of resolution cycle times of corrective actions in mobile terminals
Powered by TCPDF (www.tcpdf.org) This is an electronic reprint of the original article. This reprint may differ from the original in pagination and typographic detail. Author(s): Mwegerano, A.; Kytösaho,
More informationBiowaivers and Harmonization Guidelines for Class I and 3 Drugs: Biowaiver Case Studies
Biowaivers and Harmonization Guidelines for Class I and 3 Drugs: Biowaiver Case Studies Barbara M. Davit, Merck & Co., Inc. 3 rd FDA/PQRI Conference on Advancing Product Quality March 22, 2017 Disclaimer
More informationAnimal Research Ethics Committee. Guidelines for Submitting Protocols for ethical approval of research or teaching involving live animals
Animal Research Ethics Committee Guidelines for Submitting Protocols for ethical approval of research or teaching involving live animals AREC Document No: 3 Revised Guidelines for Submitting Protocols
More informationLIBRARY OF THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY
LIBRARY OF THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY .r ALFRED P. WORKING PAPER SLOAN SCHOOL OF MANAGEMENT STOCHASTIC CONSUMER MODELS SOME EMPIRICAL RESULTS* DAVID B. 339-68 MONTGOMERY** MASS. inst. AUG
More informationSeite 1 von 13 (February 18, 1997) All NDA, ANDA, and AADA Holders Dear Sponsors: On November 30, 1995, the Scale-up and Post-Approval Changes Guidance for Immediate Release Products (SUPAC-IR) was published.
More informationEstimation and Confidence Intervals
Estimation Estimation a statistical procedure in which a sample statistic is used to estimate the value of an unknown population parameter. Two types of estimation are: Point estimation Interval estimation
More informationAsian Journal of Pharmaceutical Research and Development
Available online on 15.04.2019 at http://ajprd.com Asian Journal of Pharmaceutical Research and Development Open Access to Pharmaceutical and Medical Research 2013-18, publisher and licensee AJPRD, This
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationOverview of Statistics used in QbD Throughout the Product Lifecycle
Overview of Statistics used in QbD Throughout the Product Lifecycle August 2014 The Windshire Group, LLC Comprehensive CMC Consulting Presentation format and purpose Method name What it is used for and/or
More informationThe Kruskal-Wallis Test with Excel In 3 Simple Steps. Kilem L. Gwet, Ph.D.
The Kruskal-Wallis Test with Excel 2007 In 3 Simple Steps Kilem L. Gwet, Ph.D. Copyright c 2011 by Kilem Li Gwet, Ph.D. All rights reserved. Published by Advanced Analytics, LLC A single copy of this document
More information